


AUTHOR QUERY FORM

 ELSEVIER	Journal: FRIN Article Number: 4454	Please e-mail or fax your responses and any corrections to: E-mail: Corrections.ESCH@elsevier.spitech.com Tel: +353-61-709642 Fax: +1 619 699 6721
---	---	--

Dear Author,

Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen annotation in the PDF file) or compile them in a separate list. Note: if you opt to annotate the file with software other than Adobe Reader then please also highlight the appropriate place in the PDF file. To ensure fast publication of your paper please return your corrections within 48 hours.

For correction or revision of any artwork, please consult <http://www.elsevier.com/artworkinstructions>.

Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in the proof. Click on the 'Q' link to go to the location in the proof.

Location in article	Query / Remark: click on the Q link to go Please insert your reply or correction at the corresponding line in the proof
Q1	Please confirm that given names and surnames have been identified correctly.
Q2	Please provide the volume number and page range for the bibliography in Ref. [Del Rio et al., 2012].
Q3	Please provide the volume number and page range for the bibliography in Ref. [Gómez-Guzmán, Jiménez, Sánchez, Zarzuelo et al., 2011].
Q4	Please provide an update for reference “Guerrero et al., in press”.
Q5	Please provide the volume number and page range for the bibliography in Ref. [Li et al., 2012].
Q6	Please provide the volume number and page range for the bibliography in Ref. [Liang et al., 2012].
Q7	Please provide the volume number and page range for the bibliography in Ref. [Martínez-Revelles et al., 2012].
Q8	Please provide the volume number and page range for the bibliography in Ref. [Quiñones et al., 2011]. <div data-bbox="641 1535 1148 1654" style="border: 1px solid black; padding: 5px; text-align: center;"> Please check this box if you have no corrections to make to the PDF file. <input type="checkbox"/> </div>

Thank you for your assistance.

Contents lists available at [SciVerse ScienceDirect](#)

Food Research International

journal homepage: www.elsevier.com/locate/foodres

Highlights

Low-molecular procyanidin rich grape seed extract exert antihypertensive effect in males spontaneously hypertensive rats (SHR)
*Food Research International xxx (2013) xxx–xxx*M. Quiñones^a, L. Guerrero^{a,b}, M. Suarez^{a,c}, Z. Pons^a, A. Aleixandre^d, L. Arola^{a,c}, B. Muguerza^{a,c,*}^a Department of Biochemistry and Biotechnology, Rovira i Virgili University, Tarragona 43007, Spain^b Department of Research, Nutrition and Innovation, ALPINA S.A, Bogotá, Colombia^c Centre Tecnològic de Nutrició i Salut (CTNS), TECNIO, CEICS, Reus 43204, Spain^d Department of Pharmacology, Faculty of Medicine, Universidad Complutense, Madrid 28040, Spain

► GSPE decreases SBP and DBP on hypertensive rats, but not in normotensive rats. ► Maximum decrease of SBP at 6 h post-administration of 375 mg/kg GSPE.
 ► GSPE increases activity of reduced glutathione, an endogenous antioxidant system. ► GSPE is rich in monomers, dimers and trimers in free form or linked to gallate. ► ACE activity and malondialdehyde, biomarker of oxidative stress, was not modified.



Contents lists available at SciVerse ScienceDirect

Food Research International

journal homepage: www.elsevier.com/locate/foodres

Low-molecular procyanidin rich grape seed extract exert antihypertensive effect in males spontaneously hypertensive rats (SHR)

M. Quiñones^a, L. Guerrero^{a,b}, M. Suarez^{a,c}, Z. Pons^a, A. Alexandre^d, L. Arola^{a,c}, B. Muguerza^{a,c,*}

^a Department of Biochemistry and Biotechnology, Rovira i Virgili University, Tarragona 43007, Spain

^b Department of Research, Nutrition and Innovation, ALPINA S.A, Bogotá, Colombia

^c Centre Tecnològic de Nutrició i Salut (CTNS), TECNIO, CEICS, Reus 43204, Spain

^d Department of Pharmacology, Faculty of Medicine, Universidad Complutense, Madrid 28040, Spain

ARTICLE INFO

Article history:

Received 13 November 2012

Accepted 10 January 2013

Available online xxx

Keywords:

Grape seed procyanidin extract

Polyphenols

Procyanidins

Hypertension

Oxidative stress

Spontaneously hypertensive rats

ABSTRACT

Grapes are a good source of flavonoids, which have been previously demonstrated to exert beneficial healthy effects on cardiovascular diseases. The aims of this study were to extensively characterise a grape seed procyanidin extract (GSPE) (total phenolic content, antioxidant capacity and HPLC–MS phenolic profile) and, to assess its antihypertensive effect in spontaneously hypertensive rats (SHR) which is a model of genetically hypertensive rat analogue to the essential hypertension in humans. The hypotensive effect of GSPE was also proved in normotensive Wistar–Kyoto rats. Chromatographic analysis of the extract showed that the most abundant polyphenols are monomers and dimers, in their free forms and linked to a gallate. GSPE produced a significant decrease in systolic and diastolic blood pressure of SHR dose-dependently up to 375 mg/kg (maximum decrease 6 h post-administration) and did not affect blood pressure of Wistar–Kyoto rats. GSPE increased the activity of an antioxidant endogen system, but did not affect plasma ACE activity in these animals.

© 2013 Published by Elsevier Ltd.

1. Introduction

Hypertension (HTN) is a major risk factor for stroke and is the most common disease found in patients in primary care (Chobanian et al., 2003). It is estimated that by 2025, the incidence of hypertension will increase to 24% in developed countries and to 80% in developing countries (Messerli, Williams, & Ritz, 2007). The current and common method for controlling hypertension is the use of long-term drug therapy. However, it is well known that drugs have many side effects, which may complicate the patient's medical condition. New strategies for treating hypertension based on natural products could greatly benefit hypertensive patients. In this context, there is evidence that a diet rich in vegetables and fruits, which are rich in flavonoids and phenolic compounds, helps to control arterial blood pressure. In fact, increased fruit and vegetable intake has been included recently in the guidelines for the management of arterial hypertension (Mancia et al., 2007).

Grapes and wine are well known as significant sources of flavonoids (Aherne & O'Brien, 2002), which exhibit several pharmacological properties, including vasodilator (Andriambeloson et al., 1997; Diebolt, Bucher, & Andriantsitohaina, 2001; Moura et al., 2002;

Zenebe, Pechanova, & Andriantsitohaina, 2003), antihypertensive (Diebolt et al., 2001; Jang & Lee, 2011) and antioxidant (Frankel, German, Kinsella, Parks, & Kanner, 1993; Jang & Lee, 2011; Moura et al., 2002) activities. These activities have led to grapes and wine being considered as functional food candidates (Barreiro-Hurlé, Colombo, & Cantos-Villar, 2008; Gollucke, 2010; Schieber, Stintzing, & Carle, 2001; Shrikhande, 2000). Nevertheless, different grape products often widely vary in both the type and content of flavonoids, and the characterisation of the types of polyphenols present in a grape variety or grape-derived product is important for understanding the possible health-promoting effects associated with its consumption. In fact, grape botanical variety/species, cultivation area, harvesting season, cultural practice, sun exposure, environmental factors, grape maturity, and manufacturing factors may affect the flavonoid content of grapes, grape extracts or wine (Aherne & O'Brien, 2002; Downey, Dokoozlian, & Krstic, 2006; Yang, Martinson, & Liu, 2009). In addition, the phenolic distribution in the juice, pulp, skins and seeds is very different; the phenolic contents of these components are approximately 5%, 1%, 30% and 64%, respectively (Singleton, 1981; Singleton & Esau, 1969). Moreover, in the grape fruit, flavonoids, such as anthocyanins and resveratrol, are mainly localised in the skins, whereas the procyanidins or flavanols are principally located in the seeds (Yang et al., 2009).

Grape seeds are a by-product of the grape/wine industry, but they are one of the richest sources of procyanidins (Nakamura, Tsuji, & Tonogai, 2003), and their beneficial effects have been extensively investigated. Our research group has demonstrated that a grape seed

* Corresponding author at: Dpto. Bioquímica y Biotecnología, University Rovira i Virgili, C/Marcel·lí Domingo s/n 43007 Tarragona, Spain. Tel.: +34 977 559566; fax: +34 977 558232.

E-mail address: begona.muguerza@urv.cat (B. Muguerza).

procyanidin-rich extract (GSPE) exhibits antioxidant capacity (Puiggròs et al., 2005), improves lipid metabolism (Del Bas et al., 2005), limits adipogenesis (Pinent et al., 2005), acts as an insulin-mimetic agent (Pinent et al., 2004) and reduces inflammation (Terra et al., 2011).

Procyanidin-rich foods, such as cocoa, have demonstrated antihypertensive properties (Buijsse, Feskens, Kok, & Kromhout, 2006; Taubert, Roesen, Lehmann, Jung, & Schömig, 2007). The antihypertensive properties of procyanidins are associated with different biological activities, such as nitric oxide-mediated vasodilation (Duffy et al., 2001; Fisher, Hughes, Gerhard-Herman, & Hollenberg, 2003; Mukai & Sato, 2009; Schroeter et al., 2006; Stein, Keevil, Wiebe, Aeschlimann, & Folts, 1999; Yamamoto, Suzuki, & Hase, 2008), angiotensin-converting enzyme (ACE) inhibition (Actis-Goretta, Ottaviani, & Fraga, 2006; Actis-Goretta, Ottaviani, Keen, & Fraga, 2003; Dong, Xu, Liang, Head, & Bennett, 2011; Ottaviani, Actis-Goretta, Villordo, & Fraga, 2006) and reduction of oxidative stress (Mane, Loonis, Juhel, Dufour, & Malien-Aubert, 2011; Ramiro-Puig et al., 2007). Although there are evidences in human studies that the whole grape fruit improves blood pressure and other factors related to vascular function in men with metabolic syndrome (Barona, Aristizabal, Blesso, Volek, & Fernandez, 2012) no investigation has yet been performed on the antihypertensive effects of GSPE in male hypertensive rats. As has been explained above, the phenolic composition of the grape seed differs from the composition of the whole grape. Therefore, it is necessary to extensively characterize the grape seed extract to better relate the resulting effects with the specific combination and concentration of molecules present in the extract.

The aims of the present study were to characterize and quantify both the flavonoid content present in GSPE and the total antioxidant capacity of this extract. We also evaluated the short-term effects of GSPE in an experimental model of hypertension. The underlying mechanisms involved in the antihypertensive effects of procyanidins have not been clarified in detail, but a better understanding of these mechanisms will allow a rational development of functional foods rich in polyphenols for blood pressure control. Therefore, in this study, we also investigated the possible mechanisms involved in the antihypertensive effects of GSPE.

2. Material and methods

2.1. Grape seed procyanidin-rich extract

The grape seed procyanidin-rich extract (GSPE) was obtained from white grape seeds and was kindly provided by Les Dérives Résiniques et Terpéniques (Dax, France). According to the manufacturer, the procyanidin profile of the extract was composed of monomers or flavan-3-ols (21.3%), dimers (17.4%), trimers (16.3%), tetramers (13.3%) and oligomers (5–13 units; 31.7%) of procyanidins.

2.2. Characterisation of GSPE

2.2.1. Solvents and phenolic standards

The following commercial standards were used for quantitative determination by HPLC: protocathechuic acid, eriodictyol-7-O-glucoside, chlorogenic acid, quercetin-3-O-galactoside, quercetin-4-O-glucoside, kaempferol-3-O-rutinoside, naringenin-7-O-glucoside, isorhamnetin-3-O-rutinoside, kaempferol-3-O-glucoside, isorhamnetin-3-O-glucoside, eriodictyol, isorhamnetin and procyanidin B2, which were purchased from Extrasynthese (Genay, France). (+)-Catechin and (–)-epicatechin were purchased from Fluka Co. (Buchs, Switzerland), and naringenin, kaempferol, vanillic acid, *p*-coumaric acid, 3-hydroxybenzoic acid, gallic acid, rutin, and (–)-epigallocatechin gallate were purchased from Sigma Aldrich (St. Louis, MO). 2,2'-Azo-bis(2-methylpropionamide) dihydrochloride (AAPH) was purchased from Acros Organics. Fluorescein was purchased from Fluka/Sigma-Aldrich (Madrid, Spain), and Folin-Ciocalteu's reagent and Trolox were purchased from Sigma (Barcelona, Spain). Organic solvents (high performance liquid chromatography

[HPLC]-grade) were obtained from Scharlab (Barcelona, Spain) and Merck (Darmstadt, Germany).

2.2.2. Quantification of the total phenolic content of GSPE

The total phenolic content of GSPE was estimated spectrophotometrically using a Hitachi U-1900 Spectrophotometer by means of the Folin-Ciocalteu assay at 725 nm (Singleton & Esau, 1969). The assay was performed in triplicate, and the samples were dissolved in ethanol:water (1:1). The results were expressed as mg of gallic acid per g of fresh GSPE extract.

2.2.3. Analysis of individual phenolic compounds of GSPE by reverse phase chromatography coupled to mass spectrometry

To study the extract in greater detail, individual phenolic compounds of the GSPE (both flavan-3-ols and phenolic acids) were characterised by an HPLC coupled to a UV detector (Agilent 1200 Series) and a time-of-flight mass spectrometer (TOF 6210, Agilent). The HPLC-MS system consisted of an Agilent 1200 Series instrument (Agilent Technologies) with a Zorbax SB-Aq column (3.5 µm, 150 mm × 2.1 mm internal diameter [i.d.]) equipped with a Pre-Column Zorbax SB-C18 (3.5 µm, 15 mm × 2.1 mm i.d.), which was also from Agilent, and Masshunter software. During the analysis, the column was kept at 30 °C and the flow rate was 0.21 mL/min. The solvent composition of solvent A was Milli-Q water/acetic acid (99.8:0.2 v/v), and that of solvent B was acetonitrile/acetic acid (99.8:0.2 v/v). Initially, 2% solvent B was used. The proportion of solvent B was gradually increased, reaching 20% at 33 min, 22.5% at 34.2 min, 23.2% at 40 min, 25% at 63 min and 100% at 72 min. Then, solvent B was reduced to the initial proportion at 75 min and maintained at this level until 90 min to re-equilibrate the column at these initial conditions. The injection volume was 9.4 µL, and all the freeze-dried samples were re-dissolved in water:acetone:acetic acid (27.5:70:0.5 v/v/v).

The wavelength of the UV detector was set at 280 nm. Ionisation in the mass spectrometer was performed by electrospray (ESI) in the negative mode, and the source parameters were as follows: capillary voltage, 4 kV; fragmentor, 125 V, source temperature, 150 °C; desolvation gas temperature, 350 °C, with a flow rate of 9 L/min and a drying gas flow rate of 12 L/min. Nitrogen was used as the cone gas.

Individual phenols were quantified with a six-point regression curve by using standards obtained from commercial suppliers.

2.2.4. Oxygen radical absorbance capacity assay

The characterisation of the GSPE was completed with the evaluation of its antioxidant activity in terms of its hydrophilic oxygen radical absorbance capacity (ORAC assay). The ORAC assay was performed according to the methodology reported previously (Huang, Ou, Hampsch-Woodill, Flanagan, & Prior, 2002) with some modifications (Suárez, Romero, Ramo, Maciá, & Motilva, 2009). This method analyses the peroxy radical-scavenging activity of the samples. The assay was performed in 96-well microplates with an FLx800 Fluorescence Microplate Reader (Bio-Tek-IZASA, Barcelona, Spain) with an excitation filter set at 485 nm and an emission filter set at 520 nm. The Gen5™ Data Analysis Software controlled the fluorescence plate reader. The experiment was performed at 37 °C in phosphate buffer at pH 7.4. The reaction mixture consisted of 150 µL of 68 nM fluorescein solution (substrate), 25 µL of 74 mM initiator solution (2,2'-Azobis(2-methylpropionamide) dihydrochloride [AAPH]; prepared immediately before use in the assay buffer at 37 °C), and 25 µL of either GSPE or Trolox at different concentrations (ranging from 0.25 to 5 µg/mL of the phenolic extract and from 12.5 to 100 µM Trolox). The assay buffer was used as a blank. The ORAC values were calculated by using the area-under-curve (AUC) results for Trolox, expressed as micromoles (µmol) of Trolox equivalents per gram of the phenolic extract, and the sample calibration curves obtained in each analysis.

208 2.3. Experimental procedure in rats

209 2.3.1. General protocol

210 In this study, we used 17–22-week-old male, spontaneously hy-
 211 pertensive rats (SHR) weighing 307.18 ± 1.64 g and 17–20-week-old
 212 male, normotensive Wistar-Kyoto (WKY) rats weighing $343.75 \pm$
 213 2.75 g. All of these animals were obtained from Charles River Labora-
 214 tories (Barcelona, Spain). The animals were maintained at 23 °C with
 215 12-h light/dark cycles and were given tap water and a standard diet
 216 (A04 Panlab, Barcelona, Spain) *ad libitum* during the experiments.
 217 GSPE was dissolved in water and orally administered by gastric intu-
 218 bation, between 9 and 10 a.m. Water was used as a negative control,
 219 and Captopril (Sigma, USA) (50 mg/kg), a known antihypertensive
 220 drug, was given as a positive control. Different doses of GSPE (250,
 221 375 and 500 mg/kg) were administered to the SHR, and 375 mg/kg
 222 GSPE was also evaluated in the Wistar-Kyoto rats. The time-length
 223 of both studies was 48 h. The animals were always orally adminis-
 224 tered either 1 mL of water or 1 mL of the appropriate solution of
 225 GSPE or Captopril. Systolic blood pressure (SBP) and diastolic blood
 226 pressure (DBP) were recorded in the rats by the tail-cuff method
 227 (Buñag, 1973) before administration and at 2, 4, 6, 8, 24 and 48 h
 228 post-administration. Before the measurements, the rats were main-
 229 tained at 38 °C for 10 min to detect the pulsations of the tail artery.
 230 Five measurements of SBP and DBP were taken, and their averages
 231 were calculated. To minimise stress-induced variations in blood pres-
 232 sure, all measurements were taken by the same person in the same
 233 peaceful environment. Moreover, to guarantee the reliability of the
 234 measurements, we established a training period of two weeks prior
 235 to the actual trial to allow the rats to become acclimated to this
 236 procedure.

237 Additionally, fifteen 22-week-old SHR were sacrificed by decapita-
 238 tion after overnight fasting. Eight of these animals were administered
 239 375 mg/kg GSPE 6 h before being sacrificed, and the remaining animals
 240 (seven) were administered water 6 h before being sacrificed. The GSPE
 241 and water were orally administered by gastric intubation, between
 242 9 and 10 a.m. Blood samples were obtained from the sacrificed rats to
 243 analyse plasma ACE activity. Liver samples were obtained from these
 244 rats to assess malondialdehyde (MDA) and reduced glutathione (GSH)
 245 levels. The procedures used to evaluate all of these parameters are
 246 described below.

247 All the above-mentioned experiments were performed as authorised
 248 for scientific research (European Directive 86/609/CEE and Royal Decree
 249 223/1988 of the Spanish Ministry of Agriculture, Fisheries and Food).

250 2.3.2. Biochemical assays

251 2.3.2.1. Plasma and liver preparations for biochemical assays. Blood
 252 samples from the sacrificed animals were collected in tubes containing
 253 sodium heparin as an anticoagulant. These samples were centrifuged at
 254 2500 g for 20 min at 4 °C to obtain the plasma, which was divided into
 255 aliquots and stored at –80 °C until analysis of ACE activity.

256 The liver tissue was homogenised at 4 °C in phosphate-buffered
 257 saline (PBS, 0.27 mM KCl, 0.15 M NaCl, 1.5 mM KH_2PO_4 , 8 mM
 258 $\text{Na}_2\text{PO}_4 \cdot \text{H}_2\text{O}$, pH 7.4) with Teflon beats (Lysing Matrix D, MP bio-
 259 medicals, Barcelona, Spain) in a Fast-Prep instrument (MP Biomedicals,
 260 Barcelona, Spain). The homogenates were centrifuged at 5000 ×g for
 261 15 min at 4 °C, and the supernatants of the centrifuged samples were
 262 stored at –80 °C until use. The protein content of the homogenates
 263 was determined using the Bio-Rad protein assay (Bio-Rad Laboratories,
 264 Hercules, CA, USA) with bovine serum albumin as the standard.

265 2.3.2.2. Malondialdehyde analysis. The MDA levels in the liver were
 266 measured by a thiobarbituric acid assay based on one proposed in
 267 the literature (Rodríguez-Martínez & Ruiz-Torres, 1992), which was
 268 modified as previously described (Manso et al., 2008). The liver
 269 homogenate was mixed with 20% trichloroacetic acid in 0.6 M HCl

(1:1, v/v), and the sample tubes were kept on ice for 20 min to pre- 270
 271 cipitate the plasma components and thus avoid any interference.
 272 The samples were centrifuged at 1500 ×g for 15 min before adding
 273 thiobarbituric acid (120 mM in Tris 260 mM, pH 7) to the superna-
 274 tant in a ratio of 1:5 (v/v). The mixture was subsequently boiled at
 275 97 °C for 30 min. Spectrophotometric measurements at 540 nm were
 276 made at 20 °C. The plasma MDA values were expressed as nmol MDA/g
 277 tissue protein.

278 2.3.2.3. Reduced glutathione assay. The GSH level in the liver was mea-
 279 sured by the monochlorobimane fluorimetric method (Kamencic, Lyon,
 280 Paterson, & Juurlink, 2000). For this analysis, 90 µL of homogenised
 281 supernatant from the liver was mixed with monochlorobimane
 282 (100 mM; Sigma, Barcelona, Spain) and 10 µL of the catalyst (gluta-
 283 thione S-transferase) solution (1 U/mL), which was obtained from
 284 horse liver (Sigma, Barcelona, Spain). The levels of GSH were quan-
 285 tified using a fluorimeterFLx800 Fluorescence Microplate Reader
 286 (Bio-Tek-IZASA, Barcelona, Spain) and were expressed as µmol/g
 287 tissue protein.

288 2.3.2.4. Determination of ACE activity in plasma. The ACE activity
 289 in plasma was measured using a fluorimetric method, as previously
 290 reported (Miguel, Alonso, Salaces, Aleixandre, & López-Fandiño, 2007).
 291 Briefly, plasma aliquots were incubated in triplicate for 15 min at 37 °C
 292 with 40 µL of assay buffer containing the ACE substrate (5 mM of
 293 Hip-His-Leu; 0.1 M sodium tetraborate decahydrate, 300 mM NaCl;
 294 pH 8.3; Sigma, Barcelona, Spain). The reaction was quenched by the
 295 addition of 190 µL of 0.35 M NaOH. The concentration of the product,
 296 His-Leu, was measured fluorimetrically after 30 min of incubation with
 297 17 µL of 2% O-phthaldialdehyde in methanol. The fluorescence measure-
 298 ments were performed at 37 °C in a FLx800 Fluorescence Microplate
 299 Reader (Bio-Tek-IZASA, Barcelona, Spain) with 350-nm excitation and
 300 520-nm emission filters and Gen5™ Data Analysis Software. Black
 301 96-well polystyrene microplates (Thermo Scientific, MERCK, Barcelona,
 302 Spain) were used. A calibration curve was constructed by adding differ-
 303 ent concentration of rabbit lung ACE (Sigma, Barcelona, Spain) to each
 304 plate. The ACE activity was expressed as mU ACE/mL of plasma.

250 2.4. Statistical analysis 305

306 The results are expressed as the mean ± standard error of the
 307 mean (SEM) and were analysed by one-way and two-way analyses
 308 of variance (ANOVA) by using the GraphPad Prism software. Differ-
 309 ences between the groups were assessed with the Bonferroni test.
 310 Differences between the means were considered to be significant
 311 when $p < 0.05$.

312 3. Results 312

313 3.1. Characterisation of GSPE 313

314 The Folin-Ciocalteu assay revealed a total phenolic content of
 315 516.8 ± 12.1 mg gallic acid equivalents/g of fresh GSPE. Fig. 1 shows
 316 the results of the analysis of the individual phenolic compounds
 317 (both flavan-3-ols and phenolic acids) by means of reversed phase
 318 HPLC–UV–MS (TOF). Table 1 presents the amounts of the identified
 319 compounds quantified using calibration curves constructed with com-
 320 mercial standards.

321 GSPE had an activity of $16,935 \pm 651$ µmol Trolox equivalents/g of
 322 fresh GSPE as determined by the ORAC assay.

323 3.2. Effects of GSPE on arterial blood pressure 323

324 Before administration of the different treatments, the SHR had a
 325 SBP of 210.60 ± 4.63 mm Hg and a DBP of 182.22 ± 4.78 mm Hg.
 326 Fig. 2 shows the changes in SBP (Fig. 2A) and DBP (Fig. 2B) observed




Fig. 1. UV-detected (280 nm) and extracted ion chromatograms (LC-TOF) of phenolic compounds from GSPE extract: (A) the HPLC–UV chromatogram of the GSPE extract at a wavelength of 280 nm and (B) the extracted ion chromatogram of the compounds included in Table 1. The results are presented as the means of three replicates, and the values in Table 1 are expressed as mg compound/g of fresh extract using the calibration curves of commercial standards. See Table 1 for codification of the peak numbers.

327 in SHR before and after the administration of water, Captopril or dif-
 328 ferent doses of GSPE. The values of SBP and DBP obtained before
 329 and after oral administration of water were very similar. Captopril
 330 (50 mg/kg) caused an obvious decrease in arterial blood pressure in
 331 SHR, and the maximum decreases in SBP and DBP were observed
 332 4 h post-administration. These variables returned to baseline 48 h
 333 after the administration of this drug. The oral administration of GSPE
 334 also resulted in significant decreases in SBP and DBP in the SHR. The

decrease in SBP caused by GSPE was dose-dependent up to 375 mg/kg, 335
 and the decrease corresponding to this dose (-48.20 ± 6.28 mm Hg), 336
 which was observed 6 h post-administration, was the maximum ob- 337
 served for this extract. Nevertheless, as for Captopril, SBP returned to 338
 baseline 48 h after the administration of 375 mg/kg GSPE. In con- 339
 trast to the results in SHR, the 375 mg/kg dose of the extract did 340
 not affect the arterial blood pressure in normotensive WKY rats 341
 (Fig. 3). The maximum decrease in SBP caused by 250 mg/kg GSPE 342

t1.1 **Table 1**
 t1.2 Individual phenolic compounds of GSPE (flavanols and phenolic acids) determined by
 t1.3 reverse-phase HPLC–MS. Values are expressed as mg compound/g extract and are the
 t1.4 means of 3 samples.

t1.5	Number	Phenolic compound	[M–H] [–]	Calibration curve	Total amount (mg/g)
t1.6	1	Gallic acid	169.0136	y = 501,094x	17.7 ± 2.0
t1.7	2	Protocatechuic acid	153.0187	y = 1,370,971.97x	1.0 ± 0.1
t1.8	3	Vanillic acid	167.0342	y = 553,787x	0.1 ± 0.0
t1.9	4, 6, 8, 13, 17	Procyanidin dimer ^a	577.1346	y = 250,456x	144.2 ± 32.2
t1.10	5	Catechin	289.0712	y = 494,478x	90.7 ± 7.6
t1.11	7	Epicatechin	289.0712	y = 556,794x	55.0 ± 0.8
t1.12	9	p-Coumaric acid	163.0395	y = 1,943,720.52x	0.1 ± 0.0
t1.13	10, 14, 16, 20, 23	Dimer gallate ^a	729.1455	y = 250,456x	39.7 ± 7.1
t1.14	11	Epigallocatechin gallate	457.0770	y = 136,996x	0.4 ± 0.1
t1.15	12	Procyanidin trimer ^a	865.1979	y = 250,456x	28.4 ± 2.0
t1.16	15	Procyanidin tetramer ^a	1153.2613	y = 250,456x	2.0 ± 0.2
t1.17	18	Epicatechin gallate ^b	441.0821	y = 556,794x	55.3 ± 1.5
t1.18	19	Quercetin-3-O-galactoside	463.0877	y = 453,509x	0.2 ± 0.0
t1.19	21	Naringenin-7-glucoside	433.1135	y = 188,637x	0.1 ± 0.0
t1.20	22	Kaempferol-3-glucoside	447.0927	y = 489,454x	0.1 ± 0.0
t1.21	24	Quercetin	301.0348	y = 704,090x	0.3 ± 0.0

t1.22 ^a Quantified using the calibration curve of procyanidin B2.
 t1.23 ^b Quantified using the calibration curve of epigallocatechin gallate.

343 (–31.77 ± 8.78 mm Hg) occurred 2 h post-administration. The de-
 344 creases in DBP caused by the 375 and 250 mg/kg GSPE doses were
 345 even greater than the decrease in DBP caused by 50 mg/kg Captopril.




Fig. 2. Decrease in systolic blood pressure (SBP) (A) and diastolic blood pressure (DBP) (B) caused in spontaneously hypertensive rats after the administration of water (○), Captopril (50 mg/kg) (□) or different doses of GSPE: 250 mg/kg (▲), 375 mg/kg (◆), 500 mg/kg (■). Data are expressed as the mean ± SEM. All of the experimental groups include a minimum of 8 animals. Different letters represent significant differences (*p* < 0.05). *p* was estimated by two-way ANOVA.




Fig. 3. Decrease in systolic blood pressure (SBP) and diastolic blood pressure (DBP) in Wistar-Kyoto rats after administration of water (○) or 375 mg/kg GSPE (◆). Data are expressed as the mean ± SEM. Both experimental groups have a minimum of 6 animals. No significant differences were observed.

The maximum decrease in DBP (–57.39 ± 7.98 mm Hg) caused by 375 mg/kg GSPE was observed 6 h post-administration in SHR. Paradoxically, 500 mg/kg GSPE exerted the lowest antihypertensive effect in SHR, as the largest changes in SBP (–19.85 ± 6.35 mm Hg) and DBP (–12.78 ± 6.25 mm Hg) caused by this dose of GSPE were less than the changes in these variables caused by the lower doses of the extract.

3.3. MDA, GSH and ACE assays

The MDA and reduced GSH levels as well as plasma ACE activity were measured in both untreated SHR and in SHR treated with 375 mg/kg GSPE 6 h after administration. The livers of GSPE-treated and untreated SHR had very similar MDA levels (Fig. 4A). The levels of reduced GSH were increased in the livers of treated SHR (Fig. 4B), whereas plasma ACE activity was similar in untreated and GSPE-treated rats 6 h after administration of 375 mg/kg GSPE (Fig. 4C).

4. Discussion

Grapes, wine and other products obtained from grapes have demonstrated many beneficial effects (Dell’Agli, Buscialà, & Bosio, 2004; Xia, Deng, Guo, & Li, 2010), including antihypertensive activity in rats (Diebolt et al., 2001; Moura et al., 2002; Peng et al., 2005; Sarr et al., 2006) and humans (Flechner-Mors, Biesalski, Jenkinson, Adler, & Ditschuneit, 2004; Hansen et al., 2005; Park, Kim, & Kang, 2004). Polyphenols are considered to be major contributors to the health benefits of grapes (Diebolt et al., 2001; Jang & Lee, 2011). However, it is important to note that not all polyphenols exhibit the same




Fig. 4. Histograms of (A) liver malondialdehyde (MDA), (B) liver reduced glutathione and (C) plasma angiotensin-converting enzyme activity (ACE) in spontaneously hypertensive rats 6 h after administration of 375 mg/kg GSPE (■) or water (□). Data are expressed as the mean ± SEM. The experimental groups include a minimum of 7 animals. Different letters represent significant differences ($p < 0.05$). p was estimated by one-way ANOVA.

bioactivity (Manach, Scalbert, Morand, Rémésy, & Jiménez, 2004; Williamson & Manach, 2005). In fact, as different grape products do not contain the same amounts or types of polyphenols (Bunea et al., 2012; Liang, Yang, Cheng, & Zhong, 2012; Liang et al., 2011), the beneficial properties of these different grape products will also not be equivalent. This fact necessitates the characterisation of these grape products to identify their bioactive constituents.

In this study, the results of the total phenolic content assay showed that phenolic compounds constituted 52% of GSPE, which supports to the substantial potential of this extract. In fact, the total polyphenol content of GSPE was 2.3 times higher than that reported for grape seeds (Pastrana-Bonilla, Akoh, Sellappan, & Krewer, 2003). The reverse-phase LC-MS analysis of the individual phenolic compounds of GSPE revealed that the most abundant phenols in GSPE

are monomers, namely catechin (90.7 mg/g GSPE) and epicatechin (55.0 mg/g GSPE), and dimers, both in their free forms and linked to gallate (144.1 and 39.7 mg/g, respectively). Reverse-phase chromatographic analysis is suitable for small compounds (up to trimers), whereas the degree of polymerisation can be determined by normal-phase chromatography (Yang & Chien, 2000). Therefore, the information obtained from our analysis is a very useful complement to the characterisation provided by the manufacturer, which indicated the extent of polymerisation.

The most abundant phenolic acid in GSPE was gallic acid (17.7 mg/g), followed by protocatechuic acid (1 mg/g). In addition, the large amounts of epicatechin and its derivatives (dimers and gallates) found in the extract are noteworthy due to the beneficial effects of these compounds, which have been demonstrated in previous studies. In fact, any concentration of plasma epicatechin is accompanied by a dose-dependent increase in the plasma antioxidant capacity (Rein et al., 2000; Serafini et al., 2003). Also, a decrease in the plasma lipid oxidation (Rein et al., 2000; Serafini et al., 2003), a beneficial effect on vascular function (Schroeter et al., 2006) and a significant reduction in the serum oxidative stress (Flammer et al., 2007) is proportionally related with epicatechin plasma concentration. In addition, recent studies have shown the antihypertensive properties of epicatechin in different rat models of hypertension (Gómez-Guzmán, Jiménez, Sánchez, Romero, et al., 2011; Gómez-Guzmán, Jiménez, Sánchez, Zarzuelo, et al., 2011).

With regard to the antioxidant activity of GSPE, it is important to state that our result of $16,935 \pm 651$ μmol Trolox equivalents/g of fresh GSPE from the ORAC assay is in agreement with an earlier result (Corrales, García, Butz, & Tauscher, 2009) of $17,180 \pm 129$ μmol Trolox equivalents/g of extract obtained from the seeds of the Riesling grape in an antioxidant assay using 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS). Moreover, the antioxidant activity of GSPE extract was higher than the antioxidant activity of an antihypertensive cocoa extract used in a previous study by our research group ($12,134 \pm 379$ μmol Trolox equivalents/g of dry extract) (Quiñones, Miguel, Muguerza, & Aleixandre, 2011).

Antioxidant therapy has been extensively studied in hypertensive patients (Kitiyakara & Wilcox, 1998), and polyphenols are well-known antioxidants (Dudonné, Vitrac, Coutière, Woillez, & Mérillon, 2009; Scalbert, Johnson, & Saltmarsh, 2005). In this study, GSPE was evaluated in SHR, the experimental animal model that best mimics essential hypertension in humans (FitzGerald, Murray, & Walsh, 2004; Okamoto & Aoki, 1963). These *in vivo* trials revealed an obvious decrease in arterial blood pressure 6 h post-administration of 375 mg/kg GSPE in SHR. This observed decrease (approximately 50 mm Hg) was a promising result because small reductions in blood pressure may have an important impact on cardiovascular events in the hypertensive population (2–3% reduction in risk for each mm Hg) (Turnbull et al., 2003). The effect of 375 mg/kg GSPE in SHR was quite similar to that of 50 mg/kg of Captopril, which is considered a very effective antihypertensive treatment in clinical practice. Therefore, we believe that GSPE could be used as an ingredient in functional foods, with potential therapeutic benefits regarding the prevention and treatment of hypertension. Nevertheless, the quantity of GSPE necessary to decrease arterial blood pressure in humans should be definitively established when clinical trials were conducted.

Paradoxically, 500 mg/kg GSPE, the highest dose of GSPE used in this study, demonstrated poorer antihypertensive effects in SHR than did the lower doses of this extract. A similar paradox could be observed with different doses of a cocoa powder and of a cocoa extract, both of which are rich in procyanidins, in SHR (Cienfuegos-Jovellanos et al., 2009; Quiñones, Miguel, Muguerza, & Aleixandre, 2011). Some researchers have proposed that a high quantity of polyphenols could exhibit pro-oxidant properties instead of antioxidant properties (Azam, Hadi, Khan, & Hadi, 2004; Cotelle, 2001; Lahouel et al., 2006). The poorer antihypertensive effect observed with increased doses of the GSPE could be attributed to this proposed effect.

The association between free radical production, lipid peroxidation, oxidative stress and hypertension is well known (Corrales et al., 2009; Martínez-Revelles et al., 2012; Quiñones, Sánchez, Muguerza, Miguel, & Aleixandre, 2011; Rodrigo, González, & Paoletto, 2011; Schulz, Gori, & Münzel, 2011). Nevertheless, it is controversial whether the anti-oxidant properties of polyphenols could explain their health benefits. Although monomeric flavan-3-ols are among those polyphenols showing higher bioavailability (Tomas-Barberán et al., 2007), they appear in the plasma not as the parent compounds, but as phase II metabolites. Morever, considerable quantities of the ingested procyanidins reach the large intestine where they are degraded by colonic microbiota, giving origin to other smaller molecules that are also absorbed into the body (Del Rio et al., 2012). Therefore, all these metabolites will be responsible of the biological effects of procyanidins, and they physiological properties are different than the original compounds ingested, including their antioxidant activities.

Many different molecular targets and mechanisms have been proposed to explain the cardiovascular effects of polyphenols. However, experimental data indicate that polyphenols present in fruits and vegetables affect endothelial function, and hence, blood pressure, by regulating the bioavailability of nitric oxide, which is known to destroy reactive oxygen species (Galleano, Pechanova, & Fraga, 2010; Quiñones, Muguerza, Miguel, & Aleixandre, 2011). In addition, activation of the deacetylase sirtuin 1 (SIRT1) and up-regulation of endothelial nitric oxide synthase (Li, Xia, & Förstermann, 2012; Mattagajasingh et al., 2007; Wallerath et al., 2002; Zhang et al., 2008) have also been proposed to explain the cardiovascular effects of polyphenols. The effects of polyphenols could also be attributed to the induction of antioxidant enzymes in cardiovascular tissues and the increased expression of γ -glutamylcysteine synthetase, the rate-limiting enzyme for glutathione synthesis (Cao & Li, 2004; Li, Cao, & Zhu, 2006; Li et al., 2012). In this study, the administration of 375 mg/kg GSPE increased liver GSH, although the levels of MDA, a biomarker of lipid peroxidation, were similar in both the GSPE-treated and untreated (water-treated) groups of SHR. Nevertheless, the rapid increase in hepatic GSH, observed only 6 h post-administration in the GSPE group of SHR, is an important result as this antioxidant molecule plays a protective role against oxidative stress and free radical damage.

Other mechanisms, such as the inhibition of ACE activity, could also explain the antihypertensive effect of GSPE. ACE plays a key role in the regulation of arterial blood pressure and procyanidins can decrease both *in vitro* (Actis-Goretta et al., 2003; Ottaviani et al., 2006) and *in vivo* ACE activity (Quiñones, Miguel, Muguerza, & Aleixandre, 2011). Although our research group has previously shown that GSPE inhibited *in vitro* ACE activity (Guerrero et al., *in press*), plasma ACE activity in the GSPE-treated SHR in the present study was very similar to the corresponding value in untreated SHR. These results could be explained by the short period of time that had elapsed after GSPE administration, which was potentially insufficient to allow the observation of changes in the activity of this enzyme.

This study demonstrates the antihypertensive effect of GSPE in SHR but not in normotensive Wistar-Kyoto rats, establishing the specific effects of GSPE on the hypertensive condition.

5. Conclusion

In conclusion, GSPE could be a potential antihypertensive ingredient for functional foods, and the improvement of oxidative stress may be one of the mechanisms involved in its beneficial effects on arterial blood pressure. Nevertheless, additional research is needed to determine the real clinical value of GSPE. Being hypertension a chronic pathology that needs chronic treatment, future studies are in particular needed to study the long-term effect of this extract, but we believe also recommendable to better clarify the mechanisms involved in its antihypertensive effect.

Acknowledgements

This study was supported by grants from the Ministerio de Educación y Ciencia of the Spanish Government (AGL 2008-00387/ALI) and the Universitat Rovira i Virgili-Banco Santander (2011 LINE-12).

References

- Actis-Goretta, L., Ottaviani, J. I., & Fraga, C. G. (2006). Inhibition of angiotensin converting enzyme activity by flavanol-rich foods. *Journal of Agricultural and Food Chemistry*, 54(1), 229–234.
- Actis-Goretta, L., Ottaviani, J. I., Keen, C. L., & Fraga, C. G. (2003). Inhibition of angiotensin converting enzyme (ACE) activity by flavan-3-ols and procyanidins. *FEBS Letters*, 555(3), 597–600.
- Aherne, S. A., & O'Brien, N. M. (2002). Dietary flavonols: Chemistry, food content, and metabolism. *Nutrition*, 18(1), 75–81.
- Andriambelosen, E., Kleschyov, A. L., Muller, B., Beretz, J., Stoclet, J. C., & Andriantsitohaina, R. (1997). Nitric oxide production and endothelium-dependent vasorelaxation induced by wine polyphenols in rat aorta. *British Journal of Pharmacology*, 120(6), 1053–1058.
- Azam, S., Hadi, N., Khan, N. U., & Hadi, S. M. (2004). Prooxidant property of green tea polyphenols epicatechin and epigallocatechin-3-gallate: Implications for anticancer properties. *Toxicology in Vitro*, 18(5), 555–561.
- Barona, J., Aristizabal, J. C., Blesso, C. N., Volek, J. S., & Fernandez, M. L. (2012). Grape polyphenols reduce blood pressure and increase flow-mediated vasodilation in men with metabolic syndrome. *Journal of Nutrition*, 142(9), 1626–1632.
- Barreiro-Hurlé, J., Colombo, S., & Cantos-Villar, E. (2008). Is there a market for functional wines? Consumer preferences and willingness to pay for resveratrol-enriched red wine. *Food Quality and Preference*, 19(4), 360–371.
- Buijsse, B., Feskens, E. J. M., Kok, F. J., & Kromhout, D. (2006). Cocoa intake, blood pressure, and cardiovascular mortality: The Zutphen Elderly Study. *Archives of Internal Medicine*, 166(4), 411.
- Buñag, R. D. (1973). Validation in awake rats of a tail-cuff method for measuring systolic pressure. *Journal of Applied Physiology*, 34(2), 279–282.
- Bunea, C. I., Pop, N., Babeş, A. C., Matea, C., Dulf, F. V., & Bunea, A. (2012). Carotenoids, total polyphenols and antioxidant activity of grapes (*Vitis vinifera*) cultivated in organic and conventional systems. *Chemistry Central Journal*, 6(1), 66.
- Cao, Z., & Li, Y. (2004). Protecting against peroxynitrite-mediated cytotoxicity in vascular smooth muscle cells via upregulating endogenous glutathione biosynthesis by 3H-1, 2-dithiole-3-thione. *Cardiovascular Toxicology*, 4(4), 339–353.
- Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., et al. (2003). Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. *Hypertension*, 42(6), 1206–1252.
- Cienfuegos-Jovellanos, E., Quiñones, M. M., Muguerza, B., Moulay, L., Miguel, M., & Aleixandre, A. (2009). Antihypertensive effect of a polyphenol-rich cocoa powder industrially processed to preserve the original flavonoids of the cocoa beans. *Journal of Agricultural and Food Chemistry*, 57(14), 6156–6162.
- Corrales, M., García, A. F., Butz, P., & Tauscher, B. (2009). Extraction of anthocyanins from grape skins assisted by high hydrostatic pressure. *Journal of Food Engineering*, 90(4), 415–421.
- Cotelle, N. (2001). Role of flavonoids in oxidative stress. *Current Topics in Medicinal Chemistry*, 1(6), 569–590.
- Del Bas, J. M., Fernández-Larrea, J., Blay, M., Ardèvol, A., Salvadó, M. J., Arola, L., et al. (2005). Grape seed procyanidins improve atherosclerotic risk index and induce liver CYP7A1 and SHP expression in healthy rats. *The FASEB Journal*, 19(3), 479–481.
- Del Rio, D., Mateos, A. M. R., Spencer, J. P. E., Massimiliano, T., Borges, G., & Crozier, A. (2012). Dietary (poly) phenolics in human health: structures, bioavailability and evidence of protective effects against chronic diseases. *Antioxidants & Redox Signaling*, 16(7), 567–602.
- Dell'Agli, M., Buscialà, A., & Bosio, E. (2004). Vascular effects of wine polyphenols. *Cardiovascular Research*, 63(4), 593–602.
- Diebolt, M., Bucher, B., & Andriantsitohaina, R. (2001). Wine polyphenols decrease blood pressure, improve NO vasodilatation, and induce gene expression. *Hypertension*, 38(2), 159–165.
- Dong, J., Xu, X., Liang, Y., Head, R., & Bennett, L. (2011). Inhibition of angiotensin converting enzyme (ACE) activity by polyphenols from tea (*Camellia sinensis*) and links to processing method. *Food and Function*, 2(6), 310–319.
- Downey, M. O., Dokoozlian, N. K., & Krstic, M. P. (2006). Cultural practice and environmental impacts on the flavonoid composition of grapes and wine: A review of recent research. *American Journal of Enology and Viticulture*, 57(3), 257–268.
- Dudonné, S., Vitrac, X., Coutière, P., Woillez, M., & Mérillon, J. M. (2009). Comparative study of antioxidant properties and total phenolic content of 30 plant extracts of industrial interest using DPPH, ABTS, FRAP, SOD, and ORAC assays. *Journal of Agricultural and Food Chemistry*, 57(5), 1768–1774.
- Duffy, S. J., Kearney, J. F., Jr., Holbrook, M., Gokce, N., Swerdloff, P. L., Frei, B., et al. (2001). Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. *Circulation*, 104(2), 151–156.
- Fisher, N. D. L., Hughes, M., Gerhard-Herman, M., & Hollenberg, N. K. (2003). Flavanol-rich cocoa induces nitric-oxide-dependent vasodilation in healthy humans. *Journal of Hypertension*, 21(12), 2281.
- FitzGerald, R. J., Murray, B. A., & Walsh, D. J. (2004). Hypotensive peptides from milk proteins. *The Journal of Nutrition*, 134(4), 980S–988S.
- Flammer, A. J., Hermann, F., Sudano, I., Spieker, L., Hermann, M., Cooper, K. A., et al. (2007). Dark chocolate improves coronary vasomotion and reduces platelet reactivity. *Circulation*, 116(21), 2376–2382.

- 595 Flechtner-Mors, M., Biesalski, H., Jenkinson, C., Adler, G., & Ditschuneit, H. (2004).
596 Effects of moderate consumption of white wine on weight loss in overweight
597 and obese subjects. *International Journal of Obesity*, 28(11), 1420–1426.
- 598 Frankel, E., German, J., Kinsella, J., Parks, E., & Kanner, J. (1993). Inhibition of oxidation
599 of human low-density lipoprotein by phenolic substances in red wine. *The Lancet*,
600 341(8843), 454–457.
- 601 Galleano, M., Pechanova, O., & Fraga, C. G. (2010). Hypertension, nitric oxide, oxidants, and
602 dietary plant polyphenols. *Current Pharmaceutical Biotechnology*, 11(8), 837–848.
- 603 Gollucke, A. P. (2010). Recent applications of grape polyphenols in foods, beverages
604 and supplements. *Recent Patents on Food, Nutrition & Agriculture*, 2(2), 105–109.
- 605 Gómez-Guzmán, M., Jiménez, R., Sánchez, M., Romero, M., O'Valle, F., Lopez-Sepulveda,
606 R., et al. (2011). Chronic (J)-epicatechin improves vascular oxidative and inflam-
607 matory status but not hypertension in chronic nitric oxide deficient rats. *British
608 Journal of Nutrition*, 106, 1337–1348.
- Q3 609 Gómez-Guzmán, M., Jiménez, R., Sánchez, M., Zarzuelo, M. J., Galindo, P., Quintela, A. M.,
610 et al. (2011). Epicatechin lowers blood pressure, restores endothelial function and
611 decreases oxidative stress, endothelin-1 and NADPH oxidase activity in DOCA-salt
612 hypertension. *Free Radical Biology & Medicine*.
- 613 Guerrero, L., Castillo, J., Quiñones, M., García-Vallvé, S., Arola, L., Pujadas, G. et al. (in press).
614 Inhibition of angiotensin-converting enzyme activity by flavonoids: Structure-activity
Q4 615 relationship studies. *PLoS ONE*.
- 616 Hansen, A. S., Marckmann, P., Dragsted, L., Nielsen, I. L. F., Nielsen, S., & Grønbaek, M.
617 (2005). Effect of red wine and red grape extract on blood lipids, haemostatic fac-
618 tors, and other risk factors for cardiovascular disease. *European Journal of Clinical
619 Nutrition*, 59(3), 449–455.
- 620 Huang, D., Ou, B., Hampsch-Woodill, M., Flanagan, J. A., & Prior, R. L. (2002).
621 High-throughput assay of oxygen radical absorbance capacity (ORAC) using a
622 multichannel liquid handling system coupled with a microplate fluorescence read-
623 er in 96-well format. *Journal of Agricultural and Food Chemistry*, 50(16), 4437–4444.
- 624 Jang, J. H., & Lee, J. S. (2011). Antihypertensive angiotensin I-converting enzyme inhibi-
625 tory activity and antioxidant activity of *Vitis* hybrid – *Vitis coignetiae* red wine
626 made with *Saccharomyces cerevisiae*. *Mycobiology*, 39(2), 137–139.
- 627 Kamencic, H., Lyon, A., Paterson, P. G., & Juurlink, B. H. J. (2000). Monochlorobimane fluo-
628 rometric method to measure tissue glutathione. *Analytical Biochemistry*, 286(1),
629 35–37.
- 630 Kitiyakara, C., & Wilcox, C. S. (1998). Antioxidants for hypertension. *Current Opinion in
631 Nephrology and Hypertension*, 7(5), 531.
- 632 Lahouel, M., Amedah, S., Zelligui, A., Touil, A., Rhouati, S., Benyache, F., et al. (2006).
633 The interaction of new plant flavonoids with rat liver mitochondria: Relation
634 between the anti- and pro-oxidant effect and flavonoids concentration. *Therapie*,
635 61(4), 347–355.
- 636 Li, Y., Cao, Z., & Zhu, H. (2006). Upregulation of endogenous antioxidants and phase 2
637 enzymes by the red wine polyphenol, resveratrol in cultured aortic smooth muscle
638 cells leads to cytoprotection against oxidative and electrophilic stress. *Pharmacological
639 Research*, 53(1), 6–15.
- Q5 640 Li, H., Xia, N., & Förstermann, U. (2012). Cardiovascular effects and molecular targets of
641 resveratrol. *Nitric Oxide*.
- 642 Liang, Z., Sang, M., Fan, P., Wu, B., Wang, L., Duan, W., et al. (2011). Changes of polyphenols,
643 sugars, and organic acid in 5 *Vitis* genotypes during berry ripening. *Journal of Food
644 Science*, 76(9), C1231–C1238.
- Q6 645 Liang, Z., Yang, Y., Cheng, L., & Zhong, G. Y. (2012). Characterization of polyphenolic
646 metabolites in the seeds of *Vitis* germplasm. *Journal of Agricultural and Food Chemistry*.
- 647 Manach, C., Scalbert, A., Morand, C., Rémésy, C., & Jiménez, L. (2004). Polyphenols: Food
648 sources and bioavailability. *The American Journal of Clinical Nutrition*, 79(5), 727–747.
- 649 Mancía, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., et al.
650 (2007). 2007 Guidelines for the management of arterial hypertension: The Task
651 Force for the Management of Arterial Hypertension of the European Society of
652 Hypertension (ESH) and of the European Society of Cardiology (ESC). *Journal of
653 Hypertension*, 25(6), 1105.
- 654 Mane, C., Loonis, M., Juhel, C., Dufour, C., & Malien-Aubert, C. (2011). Food grade ling-
655 onberry extract: Polyphenolic composition and in vivo protective effect against
656 oxidative stress. *Journal of Agricultural and Food Chemistry*, 59(7), 3330–3339.
- 657 Manso, M. A., Miguel, M., Even, J., Hernández, R., Aleixandre, A., & López-Fandiño, R.
658 (2008). Effect of the long-term intake of an egg white hydrolysate on the oxidative
659 status and blood lipid profile of spontaneously hypertensive rats. *Food Chemistry*,
660 109(2), 361–367.
- Q7 661 Martínez-Revelles, S., Avendaño, M. S., García-Redondo, A.B., Álvarez, Y., Aguado, A.,
662 Pérez-Girón, J.V., et al. (2012). Reciprocal relationship between reactive oxygen spe-
663 cies and cyclooxygenase-2 and vascular dysfunction in hypertension. *Antioxidants &
664 Redox Signaling* (ja).
- 665 Mattagajasingh, I., Kim, C. S., Naqvi, A., Yamamori, T., Hoffman, T. A., Jung, S. B., et al.
666 (2007). SIRT1 promotes endothelium-dependent vascular relaxation by activating
667 endothelial nitric oxide synthase. *Proceedings of the National Academy of Sciences*,
668 104(37), 14855.
- 669 Messerli, F. H., Williams, B., & Ritz, E. (2007). Essential hypertension. *The Lancet*, 370(9587),
670 591–603.
- 671 Miguel, M., Alonso, M. J., Saláices, M., Aleixandre, A., & López-Fandiño, R. (2007). Anti-
672 hypertensive, ACE-inhibitory and vasodilator properties of an egg white hydrolysate:
673 Effect of a simulated intestinal digestion. *Food Chemistry*, 104(1), 163–168.
- 674 Moura, R. S., Viana, F., Souza, M., Kovary, K., Guedes, D., Oliveira, E., et al. (2002). Anti-
675 hypertensive, vasodilator and antioxidant effects of a vinifera grape skin extract. *Journal of Pharmacy and Pharmacology*, 54(11), 1515–1520.
- 676 Mukai, Y., & Sato, S. (2009). Polyphenol-containing azuki bean (*Vigna angularis*) extract at-
677 tenuates blood pressure elevation and modulates nitric oxide synthase and caveolin-1
678 expressions in rats with hypertension. *Nutrition, Metabolism, and Cardiovascular
679 Diseases*, 19(7), 491–497.
- Nakamura, Y., Tsuji, S., & Tonogai, Y. (2003). Analysis of proanthocyanidins in grape 681
seed extracts, health foods and grape seed oils. *Journal of Health Science*, 49(1), 682
45–54. 683
- Okamoto, K., & Aoki, K. (1963). Development of a strain of spontaneously hypertensive 684
rats. *Japanese Circulation Journal*, 27(3), 282–293. 685
- Ottaviani, J. I., Actis-Goretta, L., Villordo, J. J., & Fraga, C. G. (2006). Procyanidin structure 686
defines the extent and specificity of angiotensin I converting enzyme inhibition. 687
Biochimie, 88(3), 359–365. 688
- Park, Y. K., Kim, J. S., & Kang, M. H. (2004). Concord grape juice supplementation reduces 689
blood pressure in Korean hypertensive men: Double blind, placebo controlled inter- 690
vention trial. *Biofactors*, 22(1–4), 145–147. 691
- Pastrana-Bonilla, E., Akoh, C. C., Sellappan, S., & Krewer, G. (2003). Phenolic content 692
and antioxidant capacity of muscadine grapes. *Journal of Agricultural and Food
693 Chemistry*, 51(18), 5497–5503. 694
- Peng, N., Clark, J. T., Prasain, J., Kim, H., White, C. R., & Wyss, J. M. (2005). Antihypertensive 695
and cognitive effects of grape polyphenols in estrogen-depleted, female, spontane- 696
ously hypertensive rats. *American Journal of Physiology – Regulatory, Integrative and
697 Comparative Physiology*, 289(3), R771–R775. 698
- Pinent, M., Blade, M., Salvado, M., Arola, L., Hackl, H., Quackenbush, J., et al. (2005). 699
Grape-seed derived procyanidins interfere with adipogenesis of 3T3-L1 cells at 700
the onset of differentiation. *International Journal of Obesity*, 29(8), 934–941. 701
- Pinent, M., Blay, M., Blade, M., Salvado, M., Arola, L., & Ardevol, A. (2004). Grape 702
seed-derived procyanidins have an antihyperglycemic effect in streptozotocin- 703
induced diabetic rats and insulinomimetic activity in insulin-sensitive cell lines. 704
Endocrinology, 145(11), 4985–4990. 705
- Puiggròs, F., Llopiz, N., Ardevol, A., Bladé, C., Arola, L., & Salvadó, M. J. (2005). Grape seed 706
procyanidins prevent oxidative injury by modulating the expression of antioxidant 707
enzyme systems. *Journal of Agricultural and Food Chemistry*, 53(15), 6080–6086. 708
- Quiñones, M., Miguel, M., Muguera, B., & Aleixandre, A. (2011). Effect of a cocoa 709
polyphenol extract in spontaneously hypertensive rats. *Food and Function*, 2(11), 710
649–653. 711
- Quiñones, M., Muguera, B., Miguel, M., & Aleixandre, A. (2011). Evidence that nitric 712 Q8
oxide mediates the blood pressure lowering effect of a polyphenol-rich cocoa powder 713
in spontaneously hypertensive rats. *Pharmacological Research*. 714
- Quiñones, M., Sánchez, D., Muguera, B., Miguel, M., & Aleixandre, A. (2011). Mecha- 715
nisms for antihypertensive effect of CocoaOX, a polyphenol-rich cocoa powder, 716
in spontaneously hypertensive rats. *Food Research International*, 44(5), 1203–1208. 717
- Ramiro-Puig, E., Urpí-Sardà, M., Pérez-Cano, F. J., Franch, À., Castellote, C., Andrés- 718
Lacueva, C., et al. (2007). Cocoa-enriched diet enhances antioxidant enzyme activity 719
and modulates lymphocyte composition in thymus from young rats. *Journal of
720 Agricultural and Food Chemistry*, 55(16), 6431–6438. 721
- Rein, D., Lotito, S., Holt, R. R., Keen, C. L., Schmitz, H. H., & Fraga, C. G. (2000). 722
Epicatechin in human plasma: in vivo determination and effect of chocolate con- 723
sumption on plasma oxidation status. *The Journal of Nutrition*, 130(8), 2109S–2114S. 724
- Rodrigo, R., González, J., & Paoletto, F. (2011). The role of oxidative stress in the patho- 725
physiology of hypertension. *Hypertension Research*, 34(4), 431–440. 726
- Rodríguez-Martínez, M., & Ruiz-Torres, A. (1992). Homeostasis between lipid peroxi- 727
dation and antioxidant enzyme activities in healthy human aging. *Mechanisms of
728 Ageing and Development*, 66(2), 213–222. 729
- Sarr, M., Chataigneau, M., Martins, S., Schott, C., El Bedoui, J., Oak, M. H., et al. (2006). 730
Red wine polyphenols prevent angiotensin II-induced hypertension and endothe- 731
lial dysfunction in rats: role of NADPH oxidase. *Cardiovascular Research*, 71(4), 732
794–802. 733
- Scalbert, A., Johnson, I. T., & Saltmarsh, M. (2005). Polyphenols: Antioxidants and beyond. 734
The American Journal of Clinical Nutrition, 81(1), 215S–217S. 735
- Schieber, A., Stintzing, F., & Carle, R. (2001). By-products of plant food processing as a 736
source of functional compounds – Recent developments. *Trends in Food Science &
737 Technology*, 12(11), 401–413. 738
- Schroeter, H., Heiss, C., Balzer, J., Kleinbongard, P., Keen, C. L., Hollenberg, N. K., et al. 739
(2006). (–)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vas- 740
cular function in humans. *Proceedings of the National Academy of Sciences of the
741 United States of America*, 103(4), 1024–1029. 742
- Schulz, E., Gori, T., & Münzel, T. (2011). Oxidative stress and endothelial dysfunction in 743
hypertension. *Hypertension Research*, 34(6), 665–673. 744
- Serafini, M., Bugianesi, R., Maiani, G., Valtuena, S., De Santis, S., & Crozier, A. (2003). 745
Plasma antioxidants from chocolate. *Nature*, 424(6952), 1013. 746
- Shrikhande, A. J. (2000). Wine by-products with health benefits. *Food Research Interna- 747
tional*, 33(6), 469–474. 748
- Singleton, V. L. (1981). Naturally occurring food toxicants: Phenolic substances of plant 749
origin common in foods. *Advances in Food Research*, 27, 149–242. 750
- Singleton, V. L., & Esau, P. (1969). Phenolic substances in grapes and wine, and their 751
significance. *Advances in Food Research*. Supplement, 1, 1–261. 752
- Stein, J. H., Keevil, J. G., Wiebe, D. A., Aeschlimann, S., & Folts, J. D. (1999). Purple grape 753
juice improves endothelial function and reduces the susceptibility of LDL chole- 754
sterol to oxidation in patients with coronary artery disease. *Circulation*, 100(10), 755
1050–1055. 756
- Suárez, M., Romero, M. P., Ramo, T., Macià, A., & Motilva, M. J. (2009). Methods for pre- 757
paring phenolic extracts from olive cake for potential application as food antioxi- 758
dants. *Journal of Agricultural and Food Chemistry*, 57(4), 1463–1472. 759
- Taubert, D., Roessen, R., Lehmann, C., Jung, N., & Schömig, E. (2007). Effects of low habitual 760
cocoa intake on blood pressure and bioactive nitric oxide. *JAMA: The Journal of the
761 American Medical Association*, 298(1), 49–60. 762
- Terra, X., Pallarés, V., Ardevol, A., Bladé, C., Fernández-Larrea, J., Pujadas, G., et al. 763
(2011). Modulatory effect of grape-seed procyanidins on local and systemic in- 764
flammation in diet-induced obesity rats. *The Journal of Nutritional Biochemistry*, 765
22(4), 380–387. 766

- 767 Tomas-Barberán, F. A., Cienfuegos-Jovellanos, E., Marín, A., Muguerza, B., Gil-Izquierdo, 783
768 Á., Cerdá, B., et al. (2007). A new process to develop a cocoa powder with higher 784
769 flavonoid monomer content and enhanced bioavailability in healthy humans. *Journal* 785
770 *of Agricultural and Food Chemistry*, 55(10), 3926–3935. 786
- 771 Turnbull, F., Neal, B., Algert, C., Chalmers, J., Woodward, M., MacMahon, S., et al. (2003). 787
772 Effects of different blood-pressure-lowering regimens on major cardiovascular 788
773 events: Results of prospectively-designed overviews of randomised trials. *Lancet*, 789
774 362(9395), 1527–1535. 790
- 775 Wallerath, T., Deckert, G., Ternes, T., Anderson, H., Li, H., Witte, K., et al. (2002). Resveratrol, 791
776 a polyphenolic phytoalexin present in red wine, enhances expression and activity of 792
777 endothelial nitric oxide synthase. *Circulation*, 106(13), 1652–1658. 793
- 778 Williamson, G., & Manach, C. (2005). Bioavailability and bioefficacy of polyphenols 794
779 in humans. II. Review of 93 intervention studies. *The American Journal of Clinical* 795
780 *Nutrition*, 81(1), 243S–255S. 796
- 781 Xia, E. Q., Deng, G. F., Guo, Y. J., & Li, H. B. (2010). Biological activities of polyphenols 797
782 from grapes. *International Journal of Molecular Sciences*, 11(2), 622–646. 798
- 799 Yamamoto, M., Suzuki, A., & Hase, T. (2008). Short-term effects of glucosyl hesperidin 800
and hesperetin on blood pressure and vascular endothelial function in spontaneously
hypertensive rats. *Journal of Nutritional Science and Vitaminology*, 54(1), 95–98.
- Yang, Y., & Chien, M. (2000). Characterization of grape procyanidins using high-
performance liquid chromatography/mass spectrometry and matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry. *Journal of Agricultural and*
Food Chemistry, 48(9), 3990–3996.
- Yang, J., Martinson, T. E., & Liu, R. H. (2009). Phytochemical profiles and antioxidant
activities of wine grapes. *Food Chemistry*, 116(1), 332–339.
- Zenebe, W., Pechanova, O., & Andriantsitohaina, R. (2003). Red wine polyphenols
induce vasorelaxation by increased nitric oxide bioactivity. *Physiological Research*,
52(4), 425–432.
- Zhang, Q., Wang, Z., Chen, H., Zhou, S., Zheng, W., Liu, G., et al. (2008).
Endothelium-specific overexpression of class III deacetylase SIRT1 decreases ath-
erosclerosis in apolipoprotein E-deficient mice. *Cardiovascular Research*, 80(2),
191–199.

UNCORRECTED PROOF